Wikipedia

Transcription factor Jun

(Redirected fromC-Jun)

Transcription factor Junis aproteinthat in humans is encoded by theJUNgene.c-Jun, in combination withprotein c-Fos,forms theAP-1early responsetranscription factor.It was first identified as the Fos-binding proteinp39and only later rediscovered as the product of the JUN gene. c-jun was the firstoncogenictranscription factor discovered.[5]The proto-oncogene c-Jun is the cellular homolog of the viraloncoproteinv-jun (P05411).[6]The viral homolog v-jun was discovered in avian sarcoma virus 17 and was named forju-nana,theJapaneseword for 17.[7]The human JUN encodes a protein that is highly similar to the viral protein, which interacts directly with specific target DNA sequences to regulategene expression.This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies.[8]

JUN
Available structures
PDBOrtholog search:PDBeRCSB
Identifiers
AliasesJUN,AP-1, AP1, c-Jun, Jun proto-oncogene, AP-1 transcription factor subunit, p39, cJUN
External IDsOMIM:165160;MGI:96646;HomoloGene:1679;GeneCards:JUN;OMA:JUN - orthologs
Orthologs
SpeciesHumanMouse
Entrez

3725

16476

Ensembl

ENSG00000177606

ENSMUSG00000052684

UniProt

P05412

P05627

RefSeq (mRNA)

NM_002228

NM_010591

RefSeq (protein)

NP_002219

NP_034721

Location (UCSC)Chr 1: 58.78 – 58.78 MbChr 4: 94.94 – 94.94 Mb
PubMedsearch[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

edit

Regulation

edit

Both Jun and its dimerization partners in AP-1 formation are subject to regulation by diverse extracellular stimuli, which include peptide growth factors, pro-inflammatorycytokines,oxidative and other forms of cellular stress, andUV irradiation.For example, UV irradiation is a potent inducer for elevated c-jun expression.[6]

As with otherimmediate early genes,induction ofc-juntranscription can occur using existing proteins in the cell, and it can be induced even when protein synthesis is blocked experimentally.[9]

c-jun transcription is autoregulated by its own product, Jun. The binding of Jun (AP-1) to a high-affinity AP-1 binding site in the jun promoter region induces jun transcription. This positive autoregulation by stimulating its own transcription may be a mechanism for prolonging the signals from extracellular stimuli. This mechanism can have biological significance for the activity of c-jun in cancer.[10][11]

Also, the c-jun activities can be regulated by the ERK pathway. Constitutively active ERK is found to increase c-jun transcription and stability through CREB and GSK3. This results in activated c-jun and its downstream targets such as RACK1 and cyclin D1. RACK1 can enhance JNK activity, and activated JNK signaling subsequently exerts regulation on c-jun activity.[12]

It is activated through double phosphorylation by theJNKpathway but has also a phosphorylation-independent function. c-junknockoutis lethal, buttransgenic animalswith a mutated c-jun that cannot bephosphorylated(termed c-junAA) can survive.

Phosphorylation of Jun at serines 63 and 73 and threonine 91 and 93 increases transcription of the c-jun target genes.[13]Therefore, regulation of c-jun activity can be achieved through N-terminal phosphorylation by the Jun N-terminal kinases (JNKs). It is shown that Jun's activity (AP-1 activity) in stress-induced apoptosis and cellular proliferation is regulated by its N-terminal phosphorylation.[14]Another study showed that oncogenic transformation by ras and fos also requires Jun N-terminal phosphorylation at Serine 63 and 73.[15]

Cell cycle progression

edit

Studies have shown that c-jun is required for progression through theG1 phaseof thecell cycle,and c-jun null cells show increased G1 arrest. C-jun regulates the transcriptional level ofcyclin D1,which is a majorRb kinase.Rb is a growth suppressor, and it is inactivated by phosphorylation. Therefore, c-jun is required for maintaining sufficient cyclin D1 kinase activity and allowing cell cycle progression.[6]

In cells absent of c-jun, the expression ofp53(cell cycle arrest inducer) andp21(CDK inhibitor and p53 target gene) is increased, and those cells exhibit cell cycle defects. Overexpression of c-jun in cells results in decreased level of p53 and p21, and exhibits accelerated cell proliferation. C-jun represses p53 transcription by binding to a variant AP-1 site in the p53 promoter. Those results indicate that c-jun downregulates p53 to control cell cycle progression.[16]

Anti-apoptotic activity

edit

UV irradiation can activate c-jun expression and the JNK signaling pathway. C-jun protects cells from UV-inducedapoptosis,and it cooperates withNF-κBto prevent apoptosis induced byTNFα.The protection from apoptosis by c-jun requires serines 63/73 (involved in phosphorylation of Jun), which is not required in c-jun-mediated G1 progress. This suggests that c-jun regulates cell cycle progression and apoptosis through two separated mechanisms.[6]

A study utilized liver-specific inactivation of c-jun in hepatocellular carcinoma, which showed impaired tumor development correlated with increased level of p53 protein and the mRNA level of the p53 target genenoxa.Also, c-jun can protect hepatocytes from apoptosis, ashepatocyteslacking c-jun showed increased sensitivity to TNFα-induced apoptosis. In those hepatocytes lacking c-jun, deletion of p53 can restore resistance toward TNFα. Those results indicate that c-jun antagonizes the proapoptotic activity of p53 in liver tumor.[17]

Clinical significance

edit

It is known that c-jun plays a role incellular proliferationand apoptosis of theendometriumthroughout themenstrual cycle.The cyclic change of the c-jun protein levels is significant in the proliferation and apoptosis of glandular epithelial cells. The persistent stromal expression of c-jun protein may preventstromal cellsfrom entering into apoptosis during the late secretory phase.[18]

Cancer

edit

In a study usingnon-small cell lung cancers(NSCLC), c-jun was found to be overexpressed in 31% of the cases in primary and metastatic lung tumors, whereas normal conducting airway and alveolar epithelia in general did not express c-jun.[19]

A study with a group consisted of 103 cases of phase I/II invasive breast cancers showed that activated c-jun is expressed predominantly at the invasive front of breast cancer and is associated with proliferation andangiogenesis.[20]

Tumor initiation

edit

A study was done with liver-specific inactivation of c-jun at different stages of tumor development in mice with chemically induced hepatocellular carcinomas. The result indicates that c-jun is required at the early stage of tumor development, and deletion of c-jun can largely suppress tumor formation. Also, c-jun is required for tumor cell survival between the initiation and progression stages. In contrast to that, inactivation of c-jun in advanced tumors does not impair tumor progression.[17]

Breast cancer

edit

Overexpression of c-jun in MCF-7 cells can result in overall increased aggressiveness, as shown by increased cellular motility, increased expression of a matrix-degrading enzymeMMP-9,increased in vitro chemoinvasion, and tumor formation in nude mice in the absence of exogenousestrogens.TheMCF-7cells with c-jun overexpression became unresponsive to estrogen and tamoxifen, thus c-jun overexpression is proposed to lead to an estrogen-independent phenotype in breast cancer cells. The observed phenotype for MCF-7 cells with c-jun overexpression is similar to that observed clinically in advanced breast cancer, which had become hormone unresponsive.[21]

The invasive phenotype contributed by c-jun overexpression is confirmed in another study. In addition, this study showed increased in vivo liver metastasis by the breast cancer with c-jun overexpression. This finding suggests that c-jun plays a critical role in the metastasis of breast cancer.[22]

In mammary tumors, endogenous c-jun was found to play a key role inErbB2-induced migration and invasion of mammary epithelial cells. Jun transcriptionally activates the promoters of SCF (stem cell factor) andCCL5.The induced SCF and CCL5 expression promotes a self-renewing mammary epithelial population. It suggests that c-jun mediates the expansion of breast cancer stem cells to enhance tumor invasiveness.[23]

Vulvar cancer

edit

C-jun has been observed overexpressed inVulvar Squamous Cell Carcinomasamples, in association with hypermethylation-Induced inactivation of theRARBtumor suppressor gene.[10]Indeed, mRNA levels of c-Jun tested higher inVulvar cancersamples when compared with those of normal skin and preneoplastic vulvar lesions, thus underscoring a cross-link between RARB gene and the oncogene c-Jun.[10]

Cellular differentiation

edit

Ten undifferentiated and highly aggressive sarcomas showed amplification of the jun gene and JUN overexpression at both RNA and protein levels. Overexpression of c-jun in 3T3-L1 cells (a preadipocytic non-tumoral cell line that resembles humanliposarcoma) can block or delay adipocytic differentiation of those cells.[24]

Nerve and spinal cord regeneration

edit

Peripheral nerve injury in rodents rapidly activates JNK signaling which in turn activates c-Jun. In contrast, nerve injury in the central nervous system does not. c-Jun is sufficient to promote axon regeneration in both the peripheral and central nervous systems as overexpression in both dorsal root ganglion neurons and cortical neurons leads to increased regeneration.[25]

As anti-cancer drug target

edit

Since c-jun has been observed overexpressed in cancer,[10]several studies highlighted the hypothesis that this gene might be a target for cancer therapy. A study showed that oncogenic transformation by ras and fos requires Jun N-terminal phosphorylation at Serine 63 and 73 by the Jun N- terminal kinases (JNK). In this study, the induced skin tumor and osteosarcoma showed impaired development in mice with a mutant Jun incapable of N-terminal phosphorylation.[15]Also, in a mouse model of intestinal cancer, genetic abrogation of Jun N-terminal phosphorylation or gut-specific c-jun inactivation attenuated cancer development and prolonged lifespan.[13]Therefore, targeting the N-terminal phosphorylation of Jun (or the JNK signaling pathway) can be a potential strategy for inhibiting tumor growth.

In melanoma-derivedB16-F10 cancer cells,c-jun inactivation by a pharmacological JNK/jun inhibitor SP combined with JunB knockdown can result in cytotoxic effect, leading to cell arrest and apoptosis. This anti-JunB /Jun strategy can increase the survival of mice inoculated with tumor cells, which suggests a potential antitumor strategy through Jun and JunB inhibition.[26]

Anti-cancer property of c-jun

edit

Most research results show that c-jun contributes to tumor initiation and increased invasiveness. However, a few studies discovered some alternative activities of c-jun, suggesting that c-jun may actually be a double-edge sword in cancer.[27]

p16

edit

p16INK4ais a tumor suppressor and a cell cycle inhibitor, and a study shows that c-jun acts as “bodyguard” to p16INK4aby preventing methylation of the p16INK4apromoter. Therefore, c-jun can prevent silencing of the gene p16INK4a.[citation needed]

Tylophorine

edit

Tylophorine is a type of plant-derived alkaloid with anticancer activity by inducing cell cycle arrest. A study demonstrated that tylophorine treatment increased c-jun protein accumulation. Then c-jun expression in conjunction with tylophorine promotes G1 arrest in carcinoma cells through the downregulation of cyclin A2. Therefore, the result indicates that the anticancer mechanism of tylophorine is mediated through c-jun.[28]

Interactions

edit

C-jun has been shown tointeractwith:

See also

edit

References

edit
  1. ^abcGRCh38: Ensembl release 89: ENSG00000177606–Ensembl,May 2017
  2. ^abcGRCm38: Ensembl release 89: ENSMUSG00000052684–Ensembl,May 2017
  3. ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^Vogt PK (June 2002). "Fortuitous convergences: the beginnings of JUN".Nature Reviews. Cancer.2(6): 465–9.doi:10.1038/nrc818.PMID12189388.S2CID44145552.
  6. ^abcdWisdom R, Johnson RS, Moore C (January 1999)."c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms".The EMBO Journal.18(1): 188–97.doi:10.1093/emboj/18.1.188.PMC1171114.PMID9878062.
  7. ^Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK (May 1987)."Avian sarcoma virus 17 carries the jun oncogene".Proceedings of the National Academy of Sciences of the United States of America.84(9): 2848–52.Bibcode:1987PNAS...84.2848M.doi:10.1073/pnas.84.9.2848.PMC304757.PMID3033666.
  8. ^"Entrez Gene: JUN jun oncogene".
  9. ^Bahrami S, Drabløs F (2016)."Gene regulation in the immediate-early response process".Advances in Biological Regulation.62:37–49.doi:10.1016/j.jbior.2016.05.001.PMID27220739.
  10. ^abcdRotondo JC, Borghi A, Selvatici R, Mazzoni E, Bononi I, Corazza M, et al. (July 2018)."Association of Retinoic Acid Receptor β Gene With Onset and Progression of Lichen Sclerosus-Associated Vulvar Squamous Cell Carcinoma".JAMA Dermatology.154(7): 819–823.doi:10.1001/jamadermatol.2018.1373.PMC6128494.PMID29898214.
  11. ^Angel P, Hattori K, Smeal T, Karin M (December 1988). "The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1".Cell.55(5): 875–85.doi:10.1016/0092-8674(88)90143-2.PMID3142689.S2CID19043736.
  12. ^Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, et al. (May 2007)."Rewired ERK-JNK signaling pathways in melanoma".Cancer Cell.11(5): 447–60.doi:10.1016/j.ccr.2007.03.009.PMC1978100.PMID17482134.
  13. ^abNateri AS, Spencer-Dene B, Behrens A (September 2005). "Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development".Nature.437(7056): 281–5.Bibcode:2005Natur.437..281N.doi:10.1038/nature03914.PMID16007074.S2CID4373376.
  14. ^Behrens A, Sibilia M, Wagner EF (March 1999). "Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation".Nature Genetics.21(3): 326–9.doi:10.1038/6854.PMID10080190.S2CID25622141.
  15. ^abBehrens A, Jochum W, Sibilia M, Wagner EF (May 2000)."Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation".Oncogene.19(22): 2657–63.doi:10.1038/sj.onc.1203603.PMID10851065.
  16. ^Schreiber M, Kolbus A, Piu F, Szabowski A, Möhle-Steinlein U, Tian J, et al. (March 1999)."Control of cell cycle progression by c-Jun is p53 dependent".Genes & Development.13(5): 607–19.doi:10.1101/gad.13.5.607.PMC316508.PMID10072388.
  17. ^abEferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, et al. (January 2003)."Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53".Cell.112(2): 181–92.doi:10.1016/S0092-8674(03)00042-4.PMID12553907.S2CID8358992.
  18. ^Udou T, Hachisuga T, Tsujioka H, Kawarabayashi T (2004). "The role of c-jun protein in proliferation and apoptosis of the endometrium throughout the menstrual cycle".Gynecologic and Obstetric Investigation.57(3): 121–6.doi:10.1159/000075701.PMID14691341.S2CID29512406.
  19. ^Szabo E, Riffe ME, Steinberg SM, Birrer MJ, Linnoila RI (January 1996). "Altered cJUN expression: an early event in human lung carcinogenesis".Cancer Research.56(2): 305–15.PMID8542585.
  20. ^Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ (June 2006). "c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer".Human Pathology.37(6): 668–74.doi:10.1016/j.humpath.2006.01.022.PMID16733206.
  21. ^Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, et al. (October 1999)."cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype".Oncogene.18(44): 6063–70.doi:10.1038/sj.onc.1202989.PMID10557095.
  22. ^Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, et al. (August 2007)."Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model".BMC Cancer.7:145.doi:10.1186/1471-2407-7-145.PMC1959235.PMID17672916.
  23. ^Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, et al. (March 2010)."c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion".The Journal of Biological Chemistry.285(11): 8218–26.doi:10.1074/jbc.M110.100792.PMC2832973.PMID20053993.
  24. ^Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O, et al. (April 2007)."JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas".Cancer Cell.11(4): 361–74.doi:10.1016/j.ccr.2007.02.007.PMID17418412.
  25. ^Mahar M, Cavalli V (June 2018)."Intrinsic mechanisms of neuronal axon regeneration".Nature Reviews. Neuroscience.19(6): 323–337.doi:10.1038/s41583-018-0001-8.PMC5987780.PMID29666508.
  26. ^Gurzov EN, Bakiri L, Alfaro JM, Wagner EF, Izquierdo M (January 2008)."Targeting c-Jun and JunB proteins as potential anticancer cell therapy".Oncogene.27(5): 641–52.doi:10.1038/sj.onc.1210690.PMID17667939.
  27. ^Eferl R, Wagner EF (November 2003). "AP-1: a double-edged sword in tumorigenesis".Nature Reviews. Cancer.3(11): 859–868.doi:10.1038/nrc1209.PMID14668816.S2CID35328722.
  28. ^Yang CW, Lee YZ, Hsu HY, Wu CM,Chang HY,Chao YS, et al. (June 2013)."c-Jun-mediated anticancer mechanisms of tylophorine".Carcinogenesis.34(6): 1304–14.doi:10.1093/carcin/bgt039.PMID23385061.
  29. ^Newell CL, Deisseroth AB, Lopez-Berestein G (July 1994). "Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF- Alpha gene".Journal of Leukocyte Biology.56(1): 27–35.doi:10.1002/jlb.56.1.27.PMID8027667.S2CID85570533.
  30. ^Kara CJ, Liou HC, Ivashkiv LB, Glimcher LH (April 1990)."A cDNA for a human cyclic AMP response element-binding protein which is distinct from CREB and expressed preferentially in brain".Molecular and Cellular Biology.10(4): 1347–57.doi:10.1128/MCB.10.4.1347.PMC362236.PMID2320002.
  31. ^abHai T, Curran T (May 1991)."Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity".Proceedings of the National Academy of Sciences of the United States of America.88(9): 3720–4.Bibcode:1991PNAS...88.3720H.doi:10.1073/pnas.88.9.3720.PMC51524.PMID1827203.
  32. ^Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, et al. (July 1997)."Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP".The Journal of Biological Chemistry.272(28): 17485–94.doi:10.1074/jbc.272.28.17485.PMID9211894.
  33. ^Jung DJ, Sung HS, Goo YW, Lee HM, Park OK, Jung SY, et al. (July 2002)."Novel transcription coactivator complex containing activating signal cointegrator 1".Molecular and Cellular Biology.22(14): 5203–11.doi:10.1128/MCB.22.14.5203-5211.2002.PMC139772.PMID12077347.
  34. ^Pearson AG, Gray CW, Pearson JF, Greenwood JM, During MJ, Dragunow M (December 2003). "ATF3 enhances c-Jun-mediated neurite sprouting".Brain Research. Molecular Brain Research.120(1): 38–45.doi:10.1016/j.molbrainres.2003.09.014.PMID14667575.
  35. ^Chen BP, Wolfgang CD, Hai T (March 1996)."Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10".Molecular and Cellular Biology.16(3): 1157–68.doi:10.1128/MCB.16.3.1157.PMC231098.PMID8622660.
  36. ^Na SY, Choi JE, Kim HJ, Jhun BH, Lee YC, Lee JW (October 1999)."Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation".The Journal of Biological Chemistry.274(40): 28491–6.doi:10.1074/jbc.274.40.28491.PMID10497212.
  37. ^Vasanwala FH, Kusam S, Toney LM, Dent AL (August 2002)."Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene".Journal of Immunology.169(4): 1922–9.doi:10.4049/jimmunol.169.4.1922.PMID12165517.
  38. ^Hu YF, Li R (June 2002)."JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction".Genes & Development.16(12): 1509–17.doi:10.1101/gad.995502.PMC186344.PMID12080089.
  39. ^Ito T, Yamauchi M, Nishina M, Yamamichi N, Mizutani T, Ui M, et al. (January 2001)."Identification of SWI.SNF complex subunit BAF60a as a determinant of the transactivation potential of Fos/Jun dimers".The Journal of Biological Chemistry.276(4): 2852–7.doi:10.1074/jbc.M009633200.PMID11053448.
  40. ^abPognonec P, Boulukos KE, Aperlo C, Fujimoto M, Ariga H, Nomoto A, et al. (May 1997)."Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity".Oncogene.14(17): 2091–8.doi:10.1038/sj.onc.1201046.PMID9160889.
  41. ^Glover JN, Harrison SC (January 1995). "Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA".Nature.373(6511): 257–61.Bibcode:1995Natur.373..257G.doi:10.1038/373257a0.PMID7816143.S2CID4276971.
  42. ^abYang X, Chen Y, Gabuzda D (September 1999)."ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB".The Journal of Biological Chemistry.274(39): 27981–8.doi:10.1074/jbc.274.39.27981.PMID10488148.
  43. ^Nomura N, Zu YL, Maekawa T, Tabata S, Akiyama T, Ishii S (February 1993)."Isolation and characterization of a novel member of the gene family encoding the cAMP response element-binding protein CRE-BP1".The Journal of Biological Chemistry.268(6): 4259–66.doi:10.1016/S0021-9258(18)53604-8.PMID8440710.
  44. ^Finkel T, Duc J, Fearon ER, Dang CV, Tomaselli GF (January 1993)."Detection and modulation in vivo of helix-loop-helix protein-protein interactions".The Journal of Biological Chemistry.268(1): 5–8.doi:10.1016/S0021-9258(18)54105-3.PMID8380166.
  45. ^abcVenugopal R, Jaiswal AK (December 1998)."Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes".Oncogene.17(24): 3145–56.doi:10.1038/sj.onc.1202237.PMID9872330.
  46. ^abYamaguchi Y, Wada T, Suzuki F, Takagi T, Hasegawa J, Handa H (August 1998)."Casein kinase II interacts with the bZIP domains of several transcription factors".Nucleic Acids Research.26(16): 3854–61.doi:10.1093/nar/26.16.3854.PMC147779.PMID9685505.
  47. ^Claret FX, Hibi M, Dhut S, Toda T, Karin M (October 1996). "A new group of conserved coactivators that increase the specificity of AP-1 transcription factors".Nature.383(6599): 453–7.Bibcode:1996Natur.383..453C.doi:10.1038/383453a0.PMID8837781.S2CID4353893.
  48. ^Sano Y, Tokitou F, Dai P, Maekawa T, Yamamoto T, Ishii S (October 1998)."CBP alleviates the intramolecular inhibition of ATF-2 function".The Journal of Biological Chemistry.273(44): 29098–105.doi:10.1074/jbc.273.44.29098.PMID9786917.
  49. ^Westermarck J, Weiss C, Saffrich R, Kast J, Musti AM, Wessely M, et al. (February 2002)."The DEXD/H-box RNA helicase RHII/Gu is a co-factor for c-Jun-activated transcription".The EMBO Journal.21(3): 451–60.doi:10.1093/emboj/21.3.451.PMC125820.PMID11823437.
  50. ^Ubeda M, Vallejo M, Habener JF (November 1999)."CHOP enhancement of gene transcription by interactions with Jun/Fos AP-1 complex proteins".Molecular and Cellular Biology.19(11): 7589–99.doi:10.1128/MCB.19.11.7589.PMC84780.PMID10523647.
  51. ^Verger A, Buisine E, Carrère S, Wintjens R, Flourens A, Coll J, et al. (May 2001)."Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation"(PDF).The Journal of Biological Chemistry.276(20): 17181–9.doi:10.1074/jbc.M010208200.PMID11278640.S2CID32288807.
  52. ^Basuyaux JP, Ferreira E, Stéhelin D, Butticè G (October 1997)."The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner".The Journal of Biological Chemistry.272(42): 26188–95.doi:10.1074/jbc.272.42.26188.PMID9334186.
  53. ^abFranklin CC, McCulloch AV, Kraft AS (February 1995)."In vitro association between the Jun protein family and the general transcription factors, TBP and TFIIB".The Biochemical Journal.305(Pt 3): 967–74.doi:10.1042/bj3050967.PMC1136352.PMID7848298.
  54. ^Ishitani T, Takaesu G, Ninomiya-Tsuji J, Shibuya H,Gaynor RB,Matsumoto K (December 2003)."Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling".The EMBO Journal.22(23): 6277–88.doi:10.1093/emboj/cdg605.PMC291846.PMID14633987.
  55. ^Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, et al. (September 1998)."ASK1 is essential for JNK/SAPK activation by TRAF2".Molecular Cell.2(3): 389–95.doi:10.1016/S1097-2765(00)80283-X.PMID9774977.
  56. ^Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. (March 1994). "JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain".Cell.76(6): 1025–37.doi:10.1016/0092-8674(94)90380-8.PMID8137421.S2CID6797795.
  57. ^Yazgan O, Pfarr CM (August 2002)."Regulation of two JunD isoforms by Jun N-terminal kinases".The Journal of Biological Chemistry.277(33): 29710–8.doi:10.1074/jbc.M204552200.PMID12052834.
  58. ^Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, et al. (September 2001)."Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death".The Journal of Biological Chemistry.276(39): 36530–4.doi:10.1074/jbc.M104837200.PMID11479302.
  59. ^Meyer CF, Wang X, Chang C, Templeton D, Tan TH (April 1996)."Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation".The Journal of Biological Chemistry.271(15): 8971–6.doi:10.1074/jbc.271.15.8971.PMID8621542.
  60. ^Cano E, Hazzalin CA, Kardalinou E, Buckle RS, Mahadevan LC (November 1995). "Neither ERK nor JNK/SAPK MAP kinase subtypes are essential for histone H3/HMG-14 phosphorylation or c-fos and c-jun induction".Journal of Cell Science.108(Pt 11): 3599–609.doi:10.1242/jcs.108.11.3599.PMID8586671.
  61. ^Tournier C, Whitmarsh AJ, Cavanagh J, Barrett T, Davis RJ (July 1997)."Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase".Proceedings of the National Academy of Sciences of the United States of America.94(14): 7337–42.Bibcode:1997PNAS...94.7337T.doi:10.1073/pnas.94.14.7337.PMC23822.PMID9207092.
  62. ^Bengal E, Ransone L, Scharfmann R, Dwarki VJ, Tapscott SJ, Weintraub H, et al. (February 1992). "Functional antagonism between c-Jun and MyoD proteins: a direct physical association".Cell.68(3): 507–19.doi:10.1016/0092-8674(92)90187-H.PMID1310896.S2CID44966899.
  63. ^Moreau A, Yotov WV, Glorieux FH, St-Arnaud R (March 1998)."Bone-specific expression of the Alpha chain of the nascent polypeptide-associated complex, a coactivator potentiating c-Jun-mediated transcription".Molecular and Cellular Biology.18(3): 1312–21.doi:10.1128/MCB.18.3.1312.PMC108844.PMID9488446.
  64. ^Zhong H, Zhu J, Zhang H, Ding L, Sun Y, Huang C, et al. (December 2004). "COBRA1 inhibits AP-1 transcriptional activity in transfected cells".Biochemical and Biophysical Research Communications.325(2): 568–73.doi:10.1016/j.bbrc.2004.10.079.PMID15530430.
  65. ^Lee SK, Kim JH, Lee YC, Cheong J, Lee JW (April 2000)."Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-kappaB, and serum response factor".The Journal of Biological Chemistry.275(17): 12470–4.doi:10.1074/jbc.275.17.12470.PMID10777532.
  66. ^Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, et al. (November 1999)."A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo".The Journal of Biological Chemistry.274(48): 34283–93.doi:10.1074/jbc.274.48.34283.PMID10567404.
  67. ^Lee SK, Na SY, Jung SY, Choi JE, Jhun BH, Cheong J, et al. (June 2000)."Activating protein-1, nuclear factor-kappaB, and serum response factor as novel target molecules of the cancer-amplified transcription coactivator ASC-2".Molecular Endocrinology.14(6): 915–25.doi:10.1210/mend.14.6.0471.PMID10847592.
  68. ^Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, et al. (July 1998)."Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits".The Journal of Biological Chemistry.273(27): 16651–4.doi:10.1074/jbc.273.27.16651.PMID9642216.
  69. ^Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, et al. (July 2001)."Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1".The EMBO Journal.20(13): 3459–72.doi:10.1093/emboj/20.13.3459.PMC125530.PMID11432833.
  70. ^Jung DJ, Na SY, Na DS, Lee JW (January 2002)."Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors".The Journal of Biological Chemistry.277(2): 1229–34.doi:10.1074/jbc.M110417200.PMID11704680.
  71. ^Nishitani J, Nishinaka T, Cheng CH, Rong W, Yokoyama KK, Chiu R (February 1999)."Recruitment of the retinoblastoma protein to c-Jun enhances transcription activity mediated through the AP-1 binding site".The Journal of Biological Chemistry.274(9): 5454–61.doi:10.1074/jbc.274.9.5454.PMID10026157.
  72. ^Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, et al. (February 2004)."Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase"(PDF).Science.303(5662): 1371–4.Bibcode:2004Sci...303.1371W.doi:10.1126/science.1093549.PMID14739464.S2CID40501515.
  73. ^Bianchi E, Denti S, Catena R, Rossetti G, Polo S, Gasparian S, et al. (May 2003)."Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity".The Journal of Biological Chemistry.278(22): 19682–90.doi:10.1074/jbc.M212681200.hdl:2434/518351.PMID12615916.
  74. ^abHess J, Porte D, Munz C, Angel P (June 2001)."AP-1 and Cbfa/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2/AP-1 composite element".The Journal of Biological Chemistry.276(23): 20029–38.doi:10.1074/jbc.M010601200.PMID11274169.
  75. ^abD'Alonzo RC, Selvamurugan N, Karsenty G, Partridge NC (January 2002)."Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation".The Journal of Biological Chemistry.277(1): 816–22.doi:10.1074/jbc.M107082200.PMID11641401.
  76. ^Zhang Y, Feng XH, Derynck R (August 1998). "Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription".Nature.394(6696): 909–13.Bibcode:1998Natur.394..909Z.doi:10.1038/29814.PMID9732876.S2CID4393852.
  77. ^Verrecchia F, Pessah M, Atfi A, Mauviel A (September 2000)."Tumor necrosis factor- Alpha inhibits transforming growth factor-beta /Smad signaling in human dermal fibroblasts via AP-1 activation".The Journal of Biological Chemistry.275(39): 30226–31.doi:10.1074/jbc.M005310200.PMID10903323.
  78. ^Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM, et al. (April 1999)."Smads bind directly to the Jun family of AP-1 transcription factors".Proceedings of the National Academy of Sciences of the United States of America.96(9): 4844–9.Bibcode:1999PNAS...96.4844L.doi:10.1073/pnas.96.9.4844.PMC21779.PMID10220381.
  79. ^abZhang X, Wrzeszczynska MH, Horvath CM, Darnell JE (October 1999)."Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation".Molecular and Cellular Biology.19(10): 7138–46.doi:10.1128/MCB.19.10.7138.PMC84707.PMID10490649.
  80. ^Pessah M, Prunier C, Marais J, Ferrand N, Mazars A, Lallemand F, et al. (May 2001)."c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity".Proceedings of the National Academy of Sciences of the United States of America.98(11): 6198–203.Bibcode:2001PNAS...98.6198P.doi:10.1073/pnas.101579798.PMC33445.PMID11371641.

Further reading

edit
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Transcription_factor_Jun&oldid=1234213027"